Literature DB >> 24267245

Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.

Kelly J Hunt1, Nathaniel Baker, Patricia Cleary, Jye-Yu Backlund, Timothy Lyons, Alicia Jenkins, Gabriel Virella, Maria F Lopes-Virella.   

Abstract

OBJECTIVE: Over 90% of modified LDL in circulation is associated to specific antibodies circulating as part of immune complexes (IC); however, few studies have examined their relationship with cardiovascular disease.
METHODS: We report the relationship between circulating concentrations of IC of oxidized LDL (oxLDL-IC), malondialdehyde-LDL (MDA-LDL-IC) and advanced glycation end products-LDL (AGE-LDL-IC) and progression of atherosclerosis over a 12 year period in 467 individuals with type 1 diabetes who participated in the Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) study. OxLDL-IC, AGE-LDL-IC and MDA-LDL-IC levels were measured at DCCT closeout. Internal carotid intima-medial thickness (IMT) was measured at EDIC follow-up years 1, 6 and 12.
RESULTS: OxLDL-IC, AGE-LDL-IC and MDA-LDL-IC levels were significantly correlated with age, lipid levels, blood pressure levels and albumin excretion rates. Levels of oxLDL, AGE-LDL and MDA-LDL in isolated LDL-IC were highly inter-correlated (r = 0.66-0.84, P < 0.0001). After adjusting for cardiovascular risk factors individuals in the upper quartile of oxLDL-IC had a 2.98-fold increased odds (CI: 1.34, 6.62) of having IMT ≥ 1.00 mm and had a 5.13-fold increased odds (CI: 1.98, 13.3) of having significant IMT progression, relative to those in the lowest quartile. Parallel odds ratios for AGE-LDL-IC were 2.95 (CI: 1.37, 6.34) and 3.50 (CI: 1.38, 8.86), while results for MDA-LDL-IC were 1.76 (0.87, 3.56) and 2.86 (1.20, 6.81).
CONCLUSION: Our study indicates that high levels of oxLDL-IC and AGE-LDL-IC are important predictors of carotid intima-medial thickening in patients with type 1 diabetes. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Carotid artery intima–media thickness; Modified LDL; Subclinical atherosclerosis; Type 1 diabetes

Mesh:

Substances:

Year:  2013        PMID: 24267245      PMCID: PMC3924569          DOI: 10.1016/j.atherosclerosis.2013.09.027

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  45 in total

1.  Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease.

Authors:  S Toshima; A Hasegawa; M Kurabayashi; H Itabe; T Takano; J Sugano; K Shimamura; J Kimura; I Michishita; T Suzuki; R Nagai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-10       Impact factor: 8.311

2.  Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.

Authors:  Gabriel Virella; Rickey E Carter; Antonio Saad; Edward G Crosswell; B Andrew Game; Maria F Lopes-Virella
Journal:  Clin Immunol       Date:  2008-06       Impact factor: 3.969

3.  Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies.

Authors:  G Virella; S Koskinen; G Krings; J M Onorato; S R Thorpe; M Lopes-Virella
Journal:  Clin Immunol       Date:  2000-05       Impact factor: 3.969

4.  Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes.

Authors:  S Ehara; M Ueda; T Naruko; K Haze; A Itoh; M Otsuka; R Komatsu; T Matsuo; H Itabe; T Takano; Y Tsukamoto; M Yoshiyama; K Takeuchi; J Yoshikawa; A E Becker
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

5.  High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.

Authors:  Maria F Lopes-Virella; Rickey E Carter; Nathaniel L Baker; John Lachin; Gabriel Virella
Journal:  Nephrol Dial Transplant       Date:  2011-08-19       Impact factor: 5.992

6.  Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.

Authors:  Maria F Lopes-Virella; Nathaniel L Baker; Kelly J Hunt; John Lachin; David Nathan; G Virella
Journal:  Atherosclerosis       Date:  2010-11-17       Impact factor: 5.162

7.  Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes.

Authors:  Maria F Lopes-Virella; Michael Brent McHenry; Stuart Lipsitz; Eunsil Yim; Peter F Wilson; Daniel T Lackland; Timothy Lyons; Alicia J Jenkins; Gabriel Virella
Journal:  Atherosclerosis       Date:  2006-03-10       Impact factor: 5.162

8.  Differential trafficking of oxidized LDL and oxidized LDL immune complexes in macrophages: impact on oxidative stress.

Authors:  Mohammed M Al Gadban; Kent J Smith; Farzan Soodavar; Christabelle Piansay; Charlyne Chassereau; Waleed O Twal; Richard L Klein; Gabriel Virella; Maria F Lopes-Virella; Samar M Hammad
Journal:  PLoS One       Date:  2010-09-02       Impact factor: 3.240

9.  Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.

Authors:  Maria F Lopes-Virella; Kelly J Hunt; Nathaniel L Baker; John Lachin; David M Nathan; G Virella
Journal:  Diabetes       Date:  2010-10-27       Impact factor: 9.461

10.  High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.

Authors:  Maria F Lopes-Virella; Nathaniel L Baker; Kelly J Hunt; Timothy J Lyons; Alicia J Jenkins; Gabriel Virella
Journal:  Diabetes Care       Date:  2012-04-17       Impact factor: 19.112

View more
  11 in total

1.  Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D.

Authors:  Arpita Basu; Ionut Bebu; Alicia J Jenkins; Julie A Stoner; Ying Zhang; Richard L Klein; Maria F Lopes-Virella; W Timothy Garvey; Matthew J Budoff; Petar Alaupovic; Timothy J Lyons
Journal:  J Lipid Res       Date:  2019-06-15       Impact factor: 5.922

2.  Immune Complexes and the Risk of CVD in Type 1 Diabetes.

Authors:  Maria F Lopes-Virella; Ionut Bebu; Kelly J Hunt; Gabriel Virella; Nathaniel L Baker; Barbara Braffett; Xiaoyu Gao; John M Lachin
Journal:  Diabetes       Date:  2019-06-19       Impact factor: 9.461

3.  ASSOCIATIONS BETWEEN ACCELERATED ATHEROSCLEROSIS, OXIDIZED LDL IMMUNE COMPLEXES, AND IN VITRO ENDOTHELIAL DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS.

Authors:  Jim C Oates; Viswanathan Ramakrishnan; Paul J Nietert; J David Spence; Thomas W Fleury; Margaret Markiewicz; Dayvia L Russell; Maria F Lopes-Virella
Journal:  Trans Am Clin Climatol Assoc       Date:  2020

Review 4.  Cardiovascular disease and type 1 diabetes: prevalence, prediction and management in an ageing population.

Authors:  Siang Ing Lee; Mitesh Patel; Christopher M Jones; Parth Narendran
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

Review 5.  Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.

Authors:  Magdalena Pertynska-Marczewska; Zaher Merhi
Journal:  Reprod Sci       Date:  2014-09-16       Impact factor: 3.060

6.  Relationship between oxidized low-density lipoprotein antibodies and obesity in different glycemic situations.

Authors:  Abdullatif Taha Babakr; Osman Mohamed Elsheikh; Abdullah A Almarzouki; Adel Mohamed Assiri; Badr Eldin Elsonni Abdalla; Hani Yousif Zaki; Samir H Fatani; EssamEldin Mohamed NourEldin
Journal:  Diabetes Metab Syndr Obes       Date:  2014-10-24       Impact factor: 3.168

7.  Skin Autofluorescence and Subclinical Atherosclerosis in Mild to Moderate Chronic Kidney Disease: A Case-Control Study.

Authors:  Enric Sánchez; Àngels Betriu; David Arroyo; Carolina López; Marta Hernández; Ferran Rius; Elvira Fernández; Albert Lecube
Journal:  PLoS One       Date:  2017-01-31       Impact factor: 3.240

Review 8.  Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.

Authors:  Alexander N Orekhov; Yuri V Bobryshev; Igor A Sobenin; Alexandra A Melnichenko; Dimitry A Chistiakov
Journal:  Int J Mol Sci       Date:  2014-07-21       Impact factor: 5.923

Review 9.  Causes of changes in carotid intima-media thickness: a literature review.

Authors:  Baoge Qu; Tao Qu
Journal:  Cardiovasc Ultrasound       Date:  2015-12-15       Impact factor: 2.062

10.  Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect.

Authors:  Gerd Hörl; Harald Froehlich; Ulrika Ferstl; Gerhard Ledinski; Josepha Binder; Gerhard Cvirn; Tatjana Stojakovic; Michael Trauner; Christoph Koidl; Erwin Tafeit; Karin Amrein; Hubert Scharnagl; Günther Jürgens; Seth Hallström
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.